SAN DIEGO, March 12, 2012 /PRNewswire/ --InflammaGen[TM] Therapeutics, a development-stage, critical care company initially focused on the diagnosis, treatment and prevention of multi-organ failure (MOF), announced today that the Company has initiated a 200-patient Phase 2 pilot study to examine the efficacy and safety of InflammaGen Shok-Pak as a potential treatment for critically ill patients in the Intensive Care Unit (ICU).
The InflammaGen Shok-Pak is the result of decades of research by University of California, San Diego Bioengineering Professor Geert Schmid-Schonbein on the microvascular and cellular reactions that lead to organ failure after a patient has gone into shock, which is the second-leading cause of in-hospital deaths in the United States.
In addition, pre-clinical studies of InflammaGen Shok-Pak in two animal species have demonstrated significant increases in long-term survival.
InflammaGen™ Therapeutics, a development-stage, critical care company initially focused on the diagnosis, treatment and prevention of Multiple Organ Failure (MOF), announced today that the Company will present a case review during BIO-Europe 2011 detailing the first-ever in-human experience involving InflammaGen Shok-Pak.
A Phase 2 pilot study of the InflammaGen Shok-Pak is expected to begin by year end 2011.
John Rodenrys, CEO of InflammaGen Therapeutics, commented, "We welcome the opportunity to present this case review at BIO-Europe 2011 to showcase the value of InflammaGen Shok-Pak as a potential treatment for shock and MOF.
We used LPS, a potent inflammagen
, as a positive control because it is a well-known activator of microglia (Facchinetti et al.
Therapeutics (a portfolio Company of Leading Biosciences) will be presenting at Boston's BioPharm America Meeting, September 9, 2011.
John Rodenrys, CEO of InflammaGen Therapeutics, remarked, "We welcome the opportunity to present Biotech Showcase 2012 to highlight the value of InflammaGen Shok-Pak as a potential treatment for shock and MOF.
Hank Loy, president of InflammaGen Therapeutics, added, "Our therapeutic and diagnostic platform is being developed to address this severe medical need, with pre-clinical research and patient experiences demonstrating a remarkable ability to reverse shock and MOF, thereby enabling those inflicted with the condition to recover and survive.
InflammaGen Therapeutics is preparing to initiate a Phase 2 Pilot Study to evaluate the potential of InflammaGen Shok-Pak to reduce morbidity in hospitalized critically ill patients.
Endotoxin is a potent inflammagen
with recognized health effects, including fever, shaking chills, septic shock, toxic pneumonitis, and respiratory symptoms.